JAMA Psychiatry

Neuroplastogen shows promise for PTSD in randomized trial

February 23, 2026

In a phase 2, 10‑week randomized trial (NCT05741710) of 65 adults with PTSD, TSND‑201 led to significantly greater reductions in CAPS‑5* total severity scores than placebo (least-squares mean difference, 9.64; 90% confidence interval, –16.48 to –2.80). Improvements also favored TSND‑201 across secondary measures, including PCL‑5,† Sheehan Disability Scale, and MADRS‡ scores. Participants received four once‑weekly oral doses without adjunct psychotherapy and were followed for 6 weeks. Common adverse events included headache, decreased appetite, nausea, dizziness, and increased blood pressure. Investigators reported that TSND‑201 was generally well tolerated.

*CAPS-5: Clinician-Administered PTSD Scales for DSM-5

†PCL-5: PTSD Checklist for DSM-5

‡MADRS: Montgomery-Åsberg Depression Rating Scale

Source:

Jones A, et al. (2026, February 18). JAMA Psychiatry. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/41706459/